Molecular & Cellular Neuroscience lab, Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana State, India.
Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana State, India.
Behav Brain Res. 2023 Jan 5;436:114081. doi: 10.1016/j.bbr.2022.114081. Epub 2022 Aug 28.
Gut microbiota, also known as the "second brain" in humans because of the regulatory role it has on the central nervous system via neuronal, chemical and immune pathways. It has been proven that there exists a bidirectional communication between the gut and the brain. Increasing evidence supports that this crosstalk is linked to the etiology and treatment of depression. Reports suggest that the gut microbiota control the host epigenetic machinery in depression and gut dysbiosis causes negative epigenetic modifications via mechanisms like histone acetylation, DNA methylation and non-coding RNA mediated gene inhibition. The gut microbiome can be a promising approach for the management of depression. The diet and dietary metabolites like kynurenine, tryptophan, and propionic acid also greatly influence the microbiome composition and thereby, the physiological activities. This review gives a bird-eye view on the pathological updates and currently used treatment approaches targeting the gut microbiota in depression.
肠道微生物群,也被称为人类的“第二大脑”,因为它通过神经元、化学和免疫途径对中枢神经系统具有调节作用。事实证明,肠道和大脑之间存在着双向通讯。越来越多的证据支持这种串扰与抑郁症的病因和治疗有关。有报道称,肠道微生物群控制着宿主在抑郁中的表观遗传机制,而肠道菌群失调通过组蛋白乙酰化、DNA 甲基化和非编码 RNA 介导的基因抑制等机制导致负性表观遗传修饰。肠道微生物组可能是治疗抑郁症的一种有前途的方法。饮食和膳食代谢产物,如犬尿氨酸、色氨酸和丙酸,也极大地影响微生物组的组成,从而影响生理活动。本综述概述了针对抑郁症中肠道微生物群的病理更新和当前使用的治疗方法。